KIF21A: A Potential Drug Target and Biomarker for Kinesin-Based Cancer Therapies

Target Name: KIF21A

NCBI ID: G55605

KIF21A

KIF21A: A Potential Drug Target and Biomarker for Kinesin-Based Cancer Therapies

Kinesin-based therapies have shown great promise in treating various types of cancer, due to their ability to target the unique dynamics of the cancer cells. One of the key components of kinesin-based therapies is the kinesin protein, which is a transmembrane protein that plays a crucial role in the proper functioning of the mitotic spindle. Kinesin-based therapies work by inhibiting the activity of the kinesin protein, leading to the collapse of the mitotic spindle and the inhibition of cell division. While these therapies have shown great promise in preclinical studies, the safety and efficacy of these treatments are still being fully defined.

KIF21A: A Potential Drug Target

The kinesin family member 21A (KIF21A) is a protein that is expressed in various tissues and cells, including cancer cells. It is a key component of the mitotic spindle and plays a crucial role in the proper functioning of this structure. KIF21A has been shown to be involved in the regulation of mitotic spindle stability and the dynamics of the kinetin protein.

Recent studies have shown that KIF21A is a potential drug target for cancer therapies. By inhibiting the activity of KIF21A, researchers have found that they can cause the collapse of the mitotic spindle, leading to the inhibition of cell division and the inhibition of the growth of cancer cells. These therapies have been shown to be effective in preclinical studies and are being further investigated as potential treatments for various types of cancer.

KIF21A as a Biomarker

In addition to its potential as a drug target, KIF21A has also been shown to be a potential biomarker for cancer. The collapse of the mitotic spindle is a key event that occurs during the execution of a cell's cycle, and is Therefore, it can be used as a marker for the treatment effect of a cancer therapy.

KIF21A has been shown to be downregulated in various types of cancer, and this downregulation has been associated with the poor prognosis of these diseases. Therefore, researchers have been interested in using KIF21A as a biomarker to predict the effectiveness of a cancer therapy. Studies have shown that KIF21A levels can be used as a marker for the treatment effect of various cancer therapies, including inhibitors of the kinesin protein itself.

Conclusion

In conclusion, KIF21A is a protein that is expressed in various tissues and cells, including cancer cells. It has been shown to be involved in the regulation of mitotic spindle stability and the dynamics of the kinetin protein. In addition to its potential as a drug target, KIF21A has also been shown to be a potential biomarker for cancer. Further studies are needed to fully define the role of KIF21A as a drug target and biomarker for cancer therapies.

Protein Name: Kinesin Family Member 21A

Functions: Microtubule-binding motor protein probably involved in neuronal axonal transport. In vitro, has a plus-end directed motor activity

The "KIF21A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIF21A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets